Reports Q4 revenue $1.61M, consensus $260,000. "Celldex made significant progress over the past year advancing our pipeline. We reported multiple positive data sets from our Phase 1b barzolvolimab program, including updated results from the Phase 1b multi-dose study in chronic spontaneous urticaria this past weekend at AAAAI," said Anthony Marucci, co-founder, president and CEO of Celldex Therapeutics. "Our Phase 2 studies in both inducible and spontaneous urticaria are enrolling as planned and we expect to complete accrual of the Phase 2 CSU study by the end of the third quarter and, importantly, will be in a position to report topline data from this study either late this year or in the first quarter of 2024."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLDX:
- Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
- Celldex presents data from barzolvolimab Phase 1b study in CSU
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
